Jen Hsun Huang sold $41M of NVDA
President and CEO at NVIDIA CORP. 225,000 shares at an average of $181.04, traded Oct 21, 2025, filed Oct 23, 2025.
Score components
- +25RoleCEO
- +25Trade size$40.7M at market
- 0Share of holdings soldSold 0.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.8%, 3m +1.5%, 6m +9.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001197649-25-000052, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 21, 2025 | SOpen-market sale Common Stock10b5-1 | -13,408 | $180.47 | $2.4M | 70,094,795 | Oct 23, 2025 |
| Oct 21, 2025 | SOpen-market sale Common Stock10b5-1 | -42,666 | $181.35 | $7.7M | 70,052,129 | Oct 23, 2025 |
| Oct 21, 2025 | SOpen-market sale Common Stock10b5-1 | -18,926 | $182.22 | $3.4M | 70,033,203 | Oct 23, 2025 |
| Oct 22, 2025 | SOpen-market sale Common Stock10b5-1 | -10,176 | $177.57 | $1.8M | 70,023,027 | Oct 23, 2025 |
| Oct 22, 2025 | SOpen-market sale Common Stock10b5-1 | -12,175 | $178.58 | $2.2M | 70,010,852 | Oct 23, 2025 |
| Oct 22, 2025 | SOpen-market sale Common Stock10b5-1 | -18,486 | $179.54 | $3.3M | 69,992,366 | Oct 23, 2025 |
| Oct 22, 2025 | SOpen-market sale Common Stock10b5-1 | -17,663 | $180.46 | $3.2M | 69,974,703 | Oct 23, 2025 |
| Oct 22, 2025 | SOpen-market sale Common Stock10b5-1 | -7,871 | $181.61 | $1.4M | 69,966,832 | Oct 23, 2025 |
| Oct 22, 2025 | SOpen-market sale Common Stock10b5-1 | -7,771 | $182.62 | $1.4M | 69,959,061 | Oct 23, 2025 |
| Oct 22, 2025 | SOpen-market sale Common Stock10b5-1 | -858 | $183.27 | $157k | 69,958,203 | Oct 23, 2025 |
| Oct 23, 2025 | SOpen-market sale Common Stock10b5-1 | -10,075 | $180.35 | $1.8M | 69,948,128 | Oct 23, 2025 |
| Oct 23, 2025 | SOpen-market sale Common Stock10b5-1 | -21,229 | $181.44 | $3.9M | 69,926,899 | Oct 23, 2025 |
| Oct 23, 2025 | SOpen-market sale Common Stock10b5-1 | -39,354 | $182.25 | $7.2M | 69,887,545 | Oct 23, 2025 |
| Oct 23, 2025 | SOpen-market sale Common Stock10b5-1 | -4,342 | $182.89 | $794k | 69,883,203 | Oct 23, 2025 |
Related signals
Other insiders at NVIDIA CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | NVIDIA CORP | Timothy S. Teter EVP, General Counsel and Sec | $6.8M 30,460 shares | -1% | |
| 75Notable | NVIDIA CORP | Mark A Stevens director | $300M 1,366,000 shares | -58% | |
| 42Moderate | NVIDIA CORP | Colette Kress EVP & Chief Financial Officer | $7.6M 34,918 shares | -4% | |
| 65Notable | NVIDIA CORP | Mark A Stevens director | $236M 1,022,239 shares | -30% | |
| 58Moderate | NVIDIA CORP | Mark A Stevens director | $411M 1,848,501 shares | -35% | |
| 28Weak | NVIDIA CORP | Timothy S. Teter EVP, General Counsel and Sec | $6.5M 30,000 shares | -1% | |
| 45Moderate | NVDAsell NVIDIA CORP | Mark A Stevens director | $186M 885,000 shares | -15% | |
| 60Notable | NVIDIA CORP | Stephen C Neal director | $3.3M 15,500 shares | -12% | |
| 60Notable | NVIDIA CORP | Mark A Stevens director | $221M 1,000,000 shares | -14% | |
| 21Weak | NVIDIA CORP | John Dabiri director | $134k 625 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.